European ATTR Amyloidosis Meeting (EU-ATTR) 2025
September 25-26, 2025 | Baveno, VB, Italy
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy based on age: The HELIOS-B trial
Clinician preferences for transthyretin amyloidosis treatment: Results from a discrete-choice experiment
Identifying unmet needs in the holistic clinical management of patients with transthyretin amyloidosis with cardiomyopathy
